Media releases

Search

20 Jul 2010

Actelion obtains option to acquire privately-held Trophos

20 Jul 2010

Actelion announces second quarter 2010 financial results

16 Jul 2010

Actelion to discuss second quarter 2010 financial results

17 May 2010

Actelion announces presentation of positive Phase II results with selexipag in patients with pulmonary arterial hypertension at the American Thoracic Society 2010 International Conference

04 May 2010

Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland

22 Apr 2010

Actelion announces first quarter 2010 financial results

09 Mar 2010

Actelion receives FDA complete response letter for Zavesca (miglustat) for the treatment of Niemann-Pick type C disease

01 Mar 2010

BUILD-3 study with bosentan in idiopathic pulmonary fibrosis does not meet primary endpoint

18 Feb 2010

Actelion publishes Annual Report 2009

18 Feb 2010

Actelion announces Full year 2009 financial results

05 Feb 2010

Actelion to Present at the 12th Annual BIO CEO & Investor Conference

12 Jan 2010

Zavesca® (miglustat) receives positive vote from the FDA's Endocrinologic and Metabolic Drugs Advisory Committee for the treatment of Niemann-Pick type C disease

11 Jan 2010

Actelion to Present at the 28th Annual J.P. Morgan Healthcare Conference

22 Dec 2009

Actelion reports arbitration results between subsidiary CoTherix, Inc. and Asahi Kasei Pharma Corporation

21 Dec 2009

Investigational dual orexin receptor antagonist almorexant meets primary endpoint in two-week phase III study in patients suffering from primary insomnia

08 Dec 2009

Actelion's selective S1P1 receptor agonist moves into advanced clinical development in psoriasis - Phase IIb dose-finding study in multiple sclerosis already ongoing - Roche to leave S1P1 alliance following comprehensive portfolio review and prioritization

19 Nov 2009

US Food and Drug Administration grants priority review for Actelion's miglustat in Niemann-Pick type C disease

20 Oct 2009

Actelion announces 9-month financial results 2009

09 Oct 2009

Dose-finding Phase IIb study started in patients with multiple sclerosis - Actelion/Roche S1P1 alliance achieves clinical milestone

08 Sep 2009

Actelion updates US Healthcare Professionals for patients with type 1 Gaucher disease - Information on the potential use of Zavesca® (miglustat) oral capsule to address the supply shortage of intravenous enzyme replacement therapy (imiglucerase)
Page : 1 2 3 4 5 6 7 8 9 10
 

Contact

Investor Relations
Actelion Pharmaceuticals Ltd
Gewerbestrasse 16
CH-4123 Allschwil
Switzerland
Phone:+41 61 565 62 62
Fax:+41 61 565 65 07
Contact us onlineHow to get to us
 
 
 

Top of page    Print pageSend this page to a friendBookmark with del.icio.usBookmark with diggBookmark with MISTER WONG